Concepedia

Author

David Köhler

National Cancer InstituteORCID

Also Known As

D KOHLER, D Kohler, D Köhler, D R Kohler, D. Kohler, D. Köhler, D. R. Kohler, D.R Kohler, D.R. Kohler, DAVID R. KOHLER

119

Publications

3.1K

Citations

28

H-Index

108

Concepts

All Affiliations

National Cancer InstituteNational Institutes of HealthNational Cancer InstituteNovartis (Switzerland)National Institutes of Health Clinical Center
DK

About

David Köhler is an author at National Cancer Institute specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

13

701

2

Engineering

3

3

139

3

Health Sciences

2

2

104

4

Business

1

1

42

5

Education

1

1

37

David Köhler

×

36

Publications

2.8K

Citations

26

H-Index

YearCitations

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

W D Figg, William Dahut, Paul H. Duray,

PubMed

2001

304

Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer

J. Zujewski, Ivan D. Horak, C.J. Bol,

Journal of Clinical Oncology

2000

265

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

Wyndham H. Wilson, G Bryant, Susan E. Bates,

Journal of Clinical Oncology

1993

244

Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.

V. Sandor, Virginia Stark-Vancs, Deborah A. Pearson,

Journal of Clinical Oncology

1998

237

Phase I Clinical Trial of Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Michelle A. Rudek, William D. Figg, Valerie Dyer,

Journal of Clinical Oncology

2001

157

Phase I study of phenylacetate administered twice daily to patients with cancer

Alain Thibault, Dvorit Samid, Michael R. Cooper,

Cancer

1995

129

Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma

Marc D. de Smet, V. S. Vancs, David Köhler,

British Journal of Ophthalmology

1999

127

A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.

Richard A. Messmann, Ellen S. Vitetta, Donna Headlee,

PubMed

2000

120

ASHP Guidelines on Preventing Medication Errors with Antineoplastic Agents

David Köhler, Michael Montello, Barry R. Goldspiel,

American Journal of Health-System Pharmacy

2002

120

A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.

Raymond C. Bergan, E Reed, Catherine E. Myers,

PubMed

1999

102

Page 1